Clinical Trial

A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To investigate the efficacy and safety of Pemafibrate 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with hypercholesterolemia and inadequate response to statins, using placebo as a control.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-14
notable Trial sites expanded: 0 -> 10 locations 2026-07-14
Trial Details
NCT Number NCT07634484
Lead Sponsor Kowa Company, Ltd.
Conditions Hypercholesterolemia
Enrollment 120 participants
Start Date 2026-07-01
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-13